AMIFOSTINE

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this trial is to compare the incidence of grade 3/4 mucositis in patients receiving amifostine (Ethyol) while undergoing HYPERRADPLAT to that of the incidence of grade 3/4 mucositis previously reported in patients who received a single injection of IA cisplatin in UK studies.